tbuckley/cabot-search huggingface dataset:
Abstract 12612: Intrapersonal and Interpersonal Factors Influencing Physical Activity in Arab Americans: A Social-Ecological Approach
Authors: Ahmed M Nahari, Leslie L Davis, Debra Wallace, Stephanie Pickett, Paul G Davis, Thomas McCoy
Journal: Circulation (2021)

Background: Physical activity (PA) is an important determinant of health throughout the lifespan. Meeting PA guidelines improves health outcomes and prevents or slows the progression of many chronic health conditions. Yet, literature has shown that many Arab Americans do not meet the PA Guidelines. Little is known about determinants of PA in this population. Objective: Guided by the Social Ecological Model, we aimed to 1) describe PA and investigate the relationships between PA and sample characteristics, intrapersonal factors, and interpersonal factors and 2) examine to what extent these factors influence PA in Arab Americans. Methods: A cross-sectional, descriptive-correlational design using a self-administered questionnaire with 140 Arab Americans was used. Spearman's rho correlation was used to assess the associations between PA and sample characteristics, intrapersonal factors, and interpersonal factors. Three simultaneous gamma regression models were used to assess to what extent sample characteristics, intrapersonal, and interpersonal factors jointly influenced PA. Results: A majority (58.6%) of our participants reported a high level of PA. Findings revealed significant positive associations between PA and health status, religiosity, and PA self-efficacy ( r s = 0.21, p = 0.019; r s = 0.19, p = 0.029; r s = 0.28; p = 0.003, respectively). Multiple regression models revealed that being employed (Model 1 Exp( b ) = 1.87, p = 0.030; Model 3 Exp( b ) = 1.77, p = 0.043) and having chronic conditions (Model 1 Exp( b ) = 1.88, p = 0.031; Model 2 Exp( b ) = 1.96, p = 0.034; Model 3 Exp( b ) = 1.91, p = 0.047) were associated with greater PA, when accounting for other sample characteristics, intrapersonal, and interpersonal factors. Conclusion: Clinicians need to recognize the importance of enhancing PA self-efficacy while considering presence of chronic health conditions and employment status when promoting PA in Arab Americans. Future research is needed to explore the relationship between religiosity and PA in this population.
Early Hematopoietic Stem Cell Transplantation in the Treatment of High-Risk Infant Leukemia
Authors: Olesia V Paina, Zhemal Zarifovna Rakhmanova, Polina Valerievna Kozhokar, Anastasia Sergeevna Frolova, Luibov Alexandrovna Tsvetkova, Anastasia Svyatoslavovna Borovkova, Kirill Alexandrovich Ekushov, Inna Viktorovna Markova, Sergey N. Bondarenko, Elena V Babenko, Aleksandr L. Alyanski, Ildar M. Barkhatov, Elena Vladimirovna Semenova, Eugene A. Bakin, Aleksandr D. Kulagin, Ivan S. Moiseev, Ludmila S Zubarovskaya
Journal: Blood (2021)
Abstract PO-107: Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer
Authors: Barbara T. Grünwald, Curtis McCloskey, Antoine Devisme, Foram Vyas, Geoffroy Andrieux, Kazeera Aliar, Faiyaz Notta, Grainne O’Kane, Julie Wilson, Jennifer Knox, Sandra Fischer, Thomas Kislinger, Melanie Boerries, Steven Gallinger, Rama Khokha
Journal: Cancer Research (2021)

Abstract Intratumoral heterogeneity is a critical frontier in understanding how the tumor microenvironment (TME) propels malignant progression. We recently deconvoluted regional heterogeneity in the human PDAC stroma to assess its role in disease progression and discovered two types of ‘sub-tumor microenvironments’ (subTMEs), called ‘reactive’ and ‘deserted’. These histologically definable tissue states exhibit strong regional relationships with tumor immunity, subtypes, differentiation, and treatment response. Here, we set out to define their cell biological underpinnings through a combination of subTME-specific cancer-associated fibroblast (CAF) models, integrative histopathology, quantitative image analysis, multiOMICs, scRNAseq, and controlled functional assays. Remarkably, the growth patterns of CAF cultures closely recapitulated the characteristic histomorphology of their originating subTMEs, and these distinct phenotypes were accompanied by behavioral differences. Unsupervised graph-based clustering of scRNAseq profiles showed that CAFs largely grouped by their originating subTME yet comprised up to 10 individual clusters. The subTME-specific multi-subpopulation CAF communities self-organized into distinct ‘coordinated states’, represented by cluster-overarching functional profiles and distinct morpho-histological and behavioral phenotypes. These differences originated in cellular differentiation trajectories, with an ‘intermediate’ transitory state evident both in single cell transcriptomics and in situ. Noticeably, this CAF differentiation potential was associated with distinct tumor-related functions and, similar to stem cells, was marked by RNA diversity and pluripotency markers. Therefore, regional TME programs in PDAC appear to result largely from transitions between subpopulation-overarching fibroblast differentiation states that guide multifaceted CAF and immune cell communities into recurrent tissue self-organizational units. Citation Format: Barbara T. Grünwald, Curtis McCloskey, Antoine Devisme, Foram Vyas, Geoffroy Andrieux, Kazeera Aliar, Faiyaz Notta, Grainne O’Kane, Julie Wilson, Jennifer Knox, Sandra Fischer, Thomas Kislinger, Melanie Boerries, Steven Gallinger, Rama Khokha. Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-107.
The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β
Authors: Mikoto Tanabe, Kohei Hosokawa, Mai Anh Thi Nguyen, Noriharu Nakagawa, Kana Maruyama, Noriaki Tsuji, Ryota Urushihara, Luis Espinoza, Mahmoud I. Elbadry, Md Mohiuddin, Takamasa Katagiri, Masanori Ono, Hiroshi Fujiwara, Kazuhisa Chonabayashi, Yoshinori Yoshida, Hirohito Yamazaki, Atsushi Hirao, Shinji Nakao
Journal: Leukemia (2021)
Pensions: BMA challenges government’s decision to make doctors pay for illegal reforms
Authors: Elisabeth Mahase
Journal: BMJ (2021)

The BMA has challenged the government’s decision to make NHS pension scheme members pick up the cost of rectifying changes to the 2015 pension scheme, which the government accepted discriminated against younger members.

In a pre-action letter to the Treasury and the Department of Health and Social Care for England, the BMA said it will challenge the government’s 2021 amendment1 that would allow it to include the full cost of reimbursing the affected members—an estimated £17bn (€19.8bn; $24bn)—in the pension scheme’s cost control mechanism.

The last pension scheme valuation in 2016 showed that members were paying too much and, under the terms of the Cost Control Mechanism, were entitled …
Have international in-person medical meetings had their day?
Authors: Richard Smith, Viknesh Sounderajah, Ara Darzi
Journal: BMJ (2021)

The pandemic has changed how conferences and meetings are conducted. <b>Richard Smith</b> says that now is the time to change the status quo forever to reduce unnecessary carbon emissions from travel. But <b>Viknesh Sounderajah</b> and <b>Ara Darzi</b> argue that going entirely virtual would lose many of the features that make meetings so valuable
Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera
Authors: Alessandra Carobbio, Alessandro Vannucchi, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Ayalew Tefferi, Valerio De Stefano, Elena Rossi, Francesco Ramundo, Arianna Masciulli, Tiziano Barbui
Journal: Blood (2021)
Artery Biomineralization and its Dissolution
Authors: Maciej Pawlikowski
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

This publication presents the results of studies on biomineralization of “atherosclerotic plaque” forming in the coronary arteries of the heart. Obtained results were compared to studies of an artery unaffected by the process of atherosclerosis. Different types of artery biomineralization were marked, in terms of both mineral and chemical composition. Theories on the formation of crystallization centers where “atherosclerotic plaque” develops were also presented. Results of preliminary in vitro studies on dissolving cholesterol and phosphate mineralization in arteries were presented. The results were interpreted, and conclusions were offered.
Deep Learning of the Retina Enables Phenome- and Genome-Wide Analyses of the Microvasculature
Authors: Seyedeh Maryam Zekavat, Vineet K. Raghu, Mark Trinder, Yixuan Ye, Satoshi Koyama, Michael C. Honigberg, Zhi Yu, Akhil Pampana, Sarah Urbut, Sara Haidermota, Declan P. O’Regan, Hongyu Zhao, Patrick T. Ellinor, Ayellet V. Segrè, Tobias Elze, Janey L. Wiggs, James Martone, Ron A. Adelman, Nazlee Zebardast, Lucian Del Priore, Jay C. Wang, Pradeep Natarajan
Journal: Circulation (2021)

The microvasculature, the smallest blood vessels in the body, has key roles in maintenance of organ health and tumorigenesis. The retinal fundus is a window for human in vivo noninvasive assessment of the microvasculature. Large-scale complementary machine learning-based assessment of the retinal vasculature with phenome-wide and genome-wide analyses may yield new insights into human health and disease.
Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma
Authors: Elena Pope, Irene Lara-Corrales, Cathryn Sibbald, Carmen Liy-Wong, Nordau Kanigsberg, Beth Drolet, Jin Ma
Journal: JAMA Pediatrics (2021)

<h3>Importance</h3> Propranolol for infantile hemangiomas (IH) has been shown to be effective and relatively safe. However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events. <h3>Objective</h3> To document the noninferiority and safety of oral nadolol compared with oral propranolol in infants with IH. <h3>Design, Setting, and Participants</h3> This double-blind noninferiority prospective study with a noninferiority margin of 10% compared propranolol with nadolol in infants aged 1 to 6 months with problematic IH. The study was conducted in 2 academic pediatric dermatology centers in Canada between 2016 and 2020. Infants aged 1 to 6 months with a hemangioma greater than 1.5 cm on the face or 3 cm or greater on another body part causing or with potential to cause functional impairment or cosmetic disfigurement. <h3>Interventions</h3> Oral propranolol and nadolol in escalating doses up to 2 mg/kg per day. <h3>Main Outcomes and Measure</h3> Between-group differences comparing changes in the bulk (size and extent) and color of the IH at week 24 with baseline using a 100-mm visual analog scale. <h3>Results</h3> The study included 71 patients. Of these, 36 were treated with propranolol. The mean (SD) age in this group was 3.1 (1.4) months, and 31 individuals (86%) were female. Thirty-five infants were treated with nadolol. The mean (SD) age in this group was 3.2 (1.6) months, and 26 individuals (74%) were female. The difference in IH between groups by<i>t</i>test was 8.8 (95% CI, 2.7-14.9) for size and 17.1 (95% CI, 7.2-30.0) for color in favor of the nadolol group, demonstrating that nadolol was noninferior to propranolol. Similar differences were noted at 52 weeks: 6.0 (95% CI, 1.9-10.1) and 10.1 (95% CI, 2.9-17.4) for size and color improvement, respectively. For each doubling of time unit (week), the coefficient of involution was 2.4 (95% CI, 0.5-4.4) higher with nadolol compared with propranolol. Safety data were similar between the 2 interventions. <h3>Conclusions and Relevance</h3> Oral nadolol was noninferior to oral propranolol, indicating it may be an efficacious and safe alternative in cases of propranolol unresponsiveness or adverse events, or when faster involution is required. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02505971
A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Authors: Meagan A. Jacoby, David A. Sallman, Bart L. Scott, Megan Haney, Fei Wan, John F. DiPersio, Ramzi Abboud, Keith E. Stockerl-Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy
Journal: Blood (2021)
Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
Authors: Jennifer Totman, Dorothy Brach, Vinny Motwani, Selene Howe, Emily Deutschman, John Lampe, Thomas V. Riera, Cuyue Tang, Sean T. Eckley, Josh Alford, Kenneth W. Duncan, Neil A. Farrow, Daniel T. Dransfield, Alejandra Raimondi, Michael J. Thomeius, Kat Cosmopoulos, Jeffery L Kutok
Journal: Blood (2021)
B Cell-Restricted Depletion of <i>Dnmt3a</i> Activates <i>Notch</i> Signaling and Causes Chronic Lymphocytic Leukemia
Authors: Shanye Yin, Anat Biran, Helene Kretzmer, Elisa Ten Hacken, Salma Parvin, Fabienne Lucas, Mohamed Uduman, Catherine Gutierrez, Nathan J Dangle, Leah Billington, Fara Regis, Laura Z. Rassenti, Arman W. Mohammad, Mei Zheng, Elizabeth Witten, Thomas J. Kipps, Jon C. Aster, Andreas Gnirke, Donna S. Neuberg, Anthony G. Letai, Lili Wang, Ruben D. Carrasco, Alexander Meissner, Catherine J. Wu
Journal: Blood (2021)
Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study
Authors: Kana Tai Lucero, Obiageri O. Obodozie-Ofoegbu, Zohra Nooruddin, Alyssa Castillo, Amanda M. Moore, Kellie J. Ryan, Xavier Jones, Christopher R. Frei
Journal: Blood (2021)
In Vivo Sol–Gel Reaction of Tantalum Alkoxide for Endovascular Embolization
Authors: Giho Ko, Jin Woo Choi, Kwangsoo Shin, Young Geon Kim, Taegyu Kang, Dokyoon Kim, Nohyun Lee, Hyo‐Cheol Kim, Taeghwan Hyeon
Journal: Advanced Healthcare Materials (2021)

Liquid embolic agents are considered the most promising for various embolization procedures because they enable deep penetration. For realizing effective procedures, the delivery of liquid embolic agents should be guided under X-ray imaging systems and the solidification time should be optimized for the specific indication. The biocompatibility of embolic agents is also crucial because they remain in the vessel after embolization. In this study, new biocompatible embolic agents based on tantalum ethoxide is synthesized. Tantalum alkoxide liquid embolics (TALE) possess the radiopacity for fluoroscopy and can control the penetration depth by modifying the sol-gel kinetics. Furthermore, TALE can serve as drug carriers for synergistic treatment. Using these excellent characteristics, it is demonstrated that TALE agents can be used in various situations including the transarterial chemoembolization of hepatocellular carcinoma and embolotherapy of massive bleeding from the femoral artery.
A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood (2021)
Comprehensive Activation Profiling of the Tabelecleucel Library, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Therapy
Authors: Joseph M Benoun, Fiona J Ruiz, Kate Widmann, Tiffany Jehng, Tassja Spindler, Jay Abraham, Sumer Minne, Karen E Tracy, Daniel Munson, Vinith Thota, Arthur Wang, Johnathan Chuan, Matt Yedwabnick, Jason A. Dubovsky
Journal: Blood (2021)
The genetic case for cardiorespiratory fitness as a clinical vital sign and the routine prescription of physical activity in healthcare
Authors: Ken B. Hanscombe, Elodie Persyn, Matthew Traylor, Kylie P. Glanville, Mark Hamer, Jonathan R. I. Coleman, Cathryn M. Lewis
Journal: Genome Medicine (2021)

Abstract Background Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and all-cause mortality. However, CRF is not routinely measured and PA not routinely prescribed as part of standard healthcare. The American Heart Association (AHA) recently presented a scientific case for the inclusion of CRF as a clinical vital sign based on epidemiological and clinical observation. Here, we leverage genetic data in the UK Biobank (UKB) to strengthen the case for CRF as a vital sign and make a case for the prescription of PA. Methods We derived two CRF measures from the heart rate data collected during a submaximal cycle ramp test: CRF-vo2max, an estimate of the participants' maximum volume of oxygen uptake, per kilogram of body weight, per minute; and CRF-slope, an estimate of the rate of increase of heart rate during exercise. Average PA over a 7-day period was derived from a wrist-worn activity tracker. After quality control, 70,783 participants had data on the two derived CRF measures, and 89,683 had PA data. We performed genome-wide association study (GWAS) analyses by sex, and post-GWAS techniques to understand genetic architecture of the traits and prioritise functional genes for follow-up. Results We found strong evidence that genetic variants associated with CRF and PA influenced genetic expression in a relatively small set of genes in the heart, artery, lung, skeletal muscle and adipose tissue. These functionally relevant genes were enriched among genes known to be associated with coronary artery disease (CAD), type 2 diabetes (T2D) and Alzheimer’s disease (three of the top 10 causes of death in high-income countries) as well as Parkinson’s disease, pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Genetic variation associated with lower CRF and PA was also correlated with several disease risk factors (including greater body mass index, body fat and multiple obesity phenotypes); a typical T2D profile (including higher insulin resistance, higher fasting glucose, impaired beta-cell function, hyperglycaemia, hypertriglyceridemia); increased risk for CAD and T2D; and a shorter lifespan. Conclusions Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign. Given the genetic, clinical and epidemiological evidence linking CRF and PA to increased morbidity and mortality, regular measurement of CRF as a marker of health and routine prescription of PA could be a prudent strategy to support public health.
Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates
Authors: Adam Bagg, Philipp Raess, Deborah Rund, Darrin Jengehino, Joanna Wiszniewska, Michelle Huynh, Abdoulaye Sanogo, Alon Horowitz, Guang Fan, Siddharth Bhattacharyya, Irit Avivi, Ben Zion Katz
Journal: Blood (2021)
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Authors: Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi
Journal: Blood (2021)
Flow Cytometric Detection of the Ki-67 Proliferation Index and the Bcl-2 Anti-Apoptotic Index in Myelodysplastic Syndromes and Acute Myeloid Leukemia, and Their Clinical Implications
Authors: Stefan G.C. Mestrum, Roanalis B.Y. Vanblarcum, Roosmarie J.M. Drent, Norbert C.J. De Wit, Bert T. Boonen, Wouter L.W. van Hemert, Anton H.N. Hopman, Frans C.S. Ramaekers, Mathie P.G. Leers
Journal: Blood (2021)
Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
Authors: Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard
Journal: Blood (2021)
Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL
Authors: Jason R. Westin, Raphael Steiner, Lei Feng, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Loretta Nastoupil, Dai Chihara, Fredrick B. Hagemeister, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Eric Davis, Michael R Green
Journal: Blood (2021)
How do you feel? A warm and touching 2021 Nobel tribute
Authors: Michael J. Caterina
Journal: Journal of Clinical Investigation (2021)

Perceptions of touch, temperature, and pain inform us about our bodies' condition and the world around us, and are critical determinants of our function, self-protection, comfort, and social interactions.Charles Sherrington, 1932 Nobel laureate, proposed that our perception of physically diverse stimuli over different intensities as distinct sensations implied the existence of correspondingly distinct neuronal mechanisms to detect these stimuli (1).Studies in the mid-1900s confirmed the existence of distinct peripheral somatosensory neuron subpopulations differentially tuned to touch, temperature, and irritant chemicals that produce a range of innocuous and noxious perceptions.However, the molecular mechanisms by which such physically distinct stimuli are detected and quantified remained enigmatic for several more decades.The 2021
A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results
Authors: Stephan A. Grupp, Selim Corbacioglu, Hyoung Jin Kang, Takanori Teshima, Michelle Zanette, Paty Lopez, Vian Amber, Antonio Pagliuca, Paul G. Richardson
Journal: Blood (2021)
Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Authors: Taylor K Mandeville, Cory Mavis, Juan Gu, Scott Olejniczak, Gyorgy Paragh, Prasenjit Dey, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2021)
Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study
Authors: Dennis A. Eichenauer, Ina Bühnen, Michael Fuchs, Helen Kaul, Carsten Kobe, Sylvia Hartmann, Christian Baues, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Journal: Blood (2021)
Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
Authors: Hannah Victoria Giles, Mark T Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J Morgan, Ruth M. de Tute, Roger G Owen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt
Journal: Blood (2021)